Systemic mastocytosis
Drug research and approvals for systemic mastocytosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 12 studies of systemic mastocytosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and FDA has 4 approved and 0 open orphan designations naming it.
- Recruiting worldwide: 12
- Trials authorized in Canada: 3
- FDA orphan approvals: 4
- EU medicines: 0
- New Italian Mastocytosis RegistryNCT07917156 · Not reported · Associazione Rete Italiana Mastocitosi · starts May 15, 2023
- Peripheral Blood KIT-D816V Mutation in Adult Systemic MastocytosisNCT07562542 · Not reported · The First Affiliated Hospital of Soochow University · starts May 19, 2025
- An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)NCT07264959 · Not reported · Blueprint Medicines Corporation · starts Apr 15, 2026
- A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in GermanyNCT07255638 · Not reported · Blueprint Medicines Corporation · starts Dec 9, 2025
- Mastocytosis From Pediatric Age to Adulthood: Local Registry of Cutaneous and Systemic MastocytosisNCT07142473 · Not reported · Fondazione IRCCS Policlinico San Matteo di Pavia · starts Jan 26, 2024
- Avapritinib Rollover StudyNCT06748001 · Phase 4 · Blueprint Medicines Corporation · starts Nov 28, 2024
- Avapritinib With Decitabine in Patients With SM-AHNNCT06327685 · Phase 1 · H. Lee Moffitt Cancer Center and Research Institute · starts Mar 13, 2024
- Angioedema Biomarker Research StudyNCT06210698 · Not reported · Foundation For Rare Disease Research · starts Jan 15, 2024
- (Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisNCT04996875 · Phase 2 · Cogent Biosciences, Inc. · starts Nov 9, 2021
Approved 1
- MidostaurinTyrosine-protein kinase receptor FLT3 inhibitor
Phase 3 1
- MasitinibFibroblast growth factor receptor 3 inhibitor
Phase 2 9
- AvapritinibStem cell growth factor receptor inhibitor
- Elenestinib
- CladribineDNA inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- Brentuximab vedotinTubulin inhibitor
- SarilumabInterleukin-6 receptor alpha subunit antagonist
- DasatinibTyrosine-protein kinase ABL inhibitor
- IbrutinibTyrosine-protein kinase BTK inhibitor
- Bezuclastinib
Phase 1 or earlier 4
- AzacitidineDNA (cytosine-5)-methyltransferase 3A inhibitor
- DecitabineDNA (cytosine-5)-methyltransferase 3A inhibitor
- CedazuridineCytidine deaminase inhibitor
- LirentelimabSialic acid-binding Ig-like lectin 8 inhibitor
How its trials ended
50 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 11 whose ending is known, 45% met their primary endpoint, 9% missed it and 45% stopped early.
- Completed, result not reported1836%
- Ongoing1734%
- Met its primary endpoint510%
- Status unknown48%
- Stopped: other or unclear36%
- Missed its primary endpoint12%
- Stopped: enrollment or feasibility12%
- Stopped: funding12%
| Nov 27, 2024 | A phase 2 multicenter study of TL-895 in subjects with myelofibrosis, indolent systemic mastocytosis, monoclonal mast cell activation syndrome, or…TL-895 (M7583) | Telios Pharmaceuticals | Ongoing |
| Dec 4, 2018 | A 3-part, randomized, double-blind, placebo-controlled phase 2 study to evaluate safety and efficacy of avapritinib (BLU-285), a selective kit…Avapritinib (BLU-285) | Sanofi | Ongoing |
| Apr 28, 2014 | A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase 3…Masitinib (AB1010) | AB Science | Pending |
| May 22, 2023 | AyvakitTreatment of adult patients with indolent systemic mastocytosis (ISM) | Sanofi US Services Inc. | Approved |
| Jun 16, 2021 | AyvakitTreatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis… | Sanofi US Services Inc. | Approved |
| Apr 28, 2017 | RydaptTreatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm… | Novartis Pharmaceuticals Corporation | Approved |
| Oct 19, 2006 | GleevecTreatment of adult patients with aggressive mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown | Novartis Pharmaceuticals Corporation | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA